Primecap Management’s Nurix Therapeutics NRIX Stock Holding History

Primecap Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-170,000	Closed	-$1.57M	–	332
2025 Q3	$1.57M	Sell	170,000 -40,000	-19%	-$415K	﹤0.01%	309
2025 Q2	$2.39M	Sell	210,000 -22,000	-9%	-$238K	﹤0.01%	304
2025 Q1	$2.76M	Hold	232,000	–	–	﹤0.01%	297
2024 Q4	$4.37M	Sell	232,000 -58,000	-20%	-$1.33M	﹤0.01%	281
2024 Q3	$6.52M	Hold	290,000	–	–	﹤0.01%	277
2024 Q2	$6.05M	Buy	290,000 +11,000	+4%	+$171K	﹤0.01%	274
2024 Q1	$4.1M	Buy	+279,000	New	+$3M	﹤0.01%	289

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management's NRIX Position: Q4 2025 in Review

Primecap Management sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 170,000 shares — an estimated $1.57M sold.

Primecap Management first reported a position in NRIX in Q1 2024 and held it in 7 quarters. The position peaked at $6.52M in Q3 2024. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

Primecap Management reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
Primecap Management sold 170,000 Nurix Therapeutics shares in Q4 2025, an estimated $1.57M.
Primecap Management first reported a position in Nurix Therapeutics in Q1 2024 and held it in 7 quarters.
Primecap Management's Nurix Therapeutics position peaked at $6.52M in Q3 2024.
182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Primecap Management's 13F filing for Q4 2025, filed 11 Feb 2026.